News for Enlivex Therapeutics Ltd Stock (ENLV)

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

GlobeNewsWire • 05/08/23

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

GlobeNewsWire • 04/19/23

Enlivex Appoints Andrew Singer to its Board of Directors

GlobeNewsWire • 04/17/23

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Accesswire • 04/14/23

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Accesswire • 04/12/23

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

GlobeNewsWire • 04/04/23

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

GlobeNewsWire • 04/03/23

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

GlobeNewsWire • 03/20/23

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

GlobeNewsWire • 02/15/23

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

GlobeNewsWire • 01/25/23

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

GlobeNewsWire • 12/05/22

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

GlobeNewsWire • 11/15/22

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

GlobeNewsWire • 10/03/22

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Seeking Alpha • 09/30/22

Enlivex to Present at Upcoming Investor and Media Conferences

GlobeNewsWire • 09/13/22

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

GlobeNewsWire • 09/12/22

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

GlobeNewsWire • 08/29/22

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

GlobeNewsWire • 08/24/22

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

GlobeNewsWire • 08/22/22

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

GlobeNewsWire • 08/17/22

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

GlobeNewsWire • 08/03/22

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

GlobeNewsWire • 07/06/22

Enlivex to Present at the 2022 Jefferies Healthcare Conference

GlobeNewsWire • 06/07/22

Enlivex Announces Upcoming May Conference Presentations

GlobeNewsWire • 05/10/22

Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

GlobeNewsWire • 05/09/22